Stuttgart, Germany - June 31, 2026

Padraig Finn appointed President Biopharma and Life Sciences

Exyte has appointed Padraig Finn as President of its Global Business Unit Biopharma and Life Sciences (BLS). He succeeds Ronan Donohue who has resigned from his position as President Biopharma & Life Sciences. He will leave Exyte effective 31 July 2026 to pursue other opportunities outside of the company.

Finn assumes the role after serving as Senior Vice President Market and Client Strategy in the Business Unit. In this position, he has been responsible for market development, strategic customer engagement, and supporting the continued growth of Exyte's Biopharma and Life Sciences business. BLS is Exyte's second-largest Global Business Unit in terms of sales and achieved a record order intake in 2025.

 

Peter Schönhofer, CEO and CFO of Exyte, says: "Padraig has made a significant contribution to the development of our Biopharma & Life Sciences business through his work as Senior Vice President Market and Client Strategy. Through his many years in the industry, he has built robust relationships across the global biopharma and life sciences sector and has a deep understanding of our clients and markets. His experience, industry network and strategic perspective make him ideally positioned to lead our Biopharma & Life Sciences business and support its continued growth. 

 

I would also like to thank Ronan for his contributions to Exyte and our Biopharma and Life Sciences business. We wish him all the best in his future endeavors."

 
Head of Corporate Communications and Investor Relations

Head of Corporate Communications and Investor Relations

René Ziegler

 

For any further question or should you require additional information please feel free to contact:

 

rene.ziegler@exyte.net

 

Please understand that our press office can only answer questions from journalists. Please refer to our general contact email for contacts on other
matters.